Program
Travoprost
Also written as “Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)”, “Travoprost 0.004% / Timolol maleate 0.5%” and “Travoprost 0.004% ophthalmic solution”.
Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Glaucoma, Angle-Closure · Low Tension Glaucoma · Hydrophthalmos, led by 5 companies.
Drug pageTravoprost: every studyMany companies study it; this page follows only the 63 they lead. All 80 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alconits history only | 520 open or running | phase 4since May 28, 2003 | Jan 3, 2003 | none ahead |
| Glaukosits history only | 72 open or running | phase 4since Sep 28, 2011 | Sep 28, 2011 | none ahead |
| Ocular Therapeutixits history only | 20 open or running | phase 3since Sep 21, 2016 | Dec 4, 2014 | none ahead |
| Laboratorios Sophia S.A de C.V.its history only | 10 open or running | phase 1since May 23, 2019 | May 23, 2019 | none ahead |
| Viatrisits history only | 10 open or running | phase 4since Feb 16, 2009 | Feb 16, 2009 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since May 28, 2003.
- Jul 26, 2012Phase 3 study in HydrophthalmosAlcon · NCT01652664 · 184 enrolled
- Aug 3, 2012Phase 1 study in GlaucomaAlcon · NCT01658839 · 25 enrolled
- Aug 10, 2012Phase 4 study in GlaucomaAlcon · NCT01664039 · 104 enrolled
- Sep 27, 2012Phase 4 study in GlaucomaAlcon · NCT01696383
- Nov 21, 2013Phase 4 study in Low Tension GlaucomaAlcon · NCT01995136 · 32 enrolled · Japan
- Dec 2, 2013Phase 4 study in Glaucoma, Open-AngleAlcon · NCT02003391 · 157 enrolled
- Dec 4, 2014Ocular Therapeutix’s first study: phase 2 study in GlaucomaNew to Ocular TherapeutixOcular Therapeutix · NCT02312544 · 72 enrolled · United States
- Aug 11, 2016Phase 4 study in Glaucoma, Open-AngleGlaukos · NCT02873806 · 53 enrolled · Armenia
- Sep 21, 2016Phase 3 study in Glaucoma, Open-AngleOcular Therapeutix · NCT02914509 · 565 enrolled · United States
- May 23, 2019Laboratorios Sophia S.A de C.V.’s first study: phase 1 study in GlaucomaNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT03965052 · 24 enrolled · Mexico
- Oct 29, 2020Phase 2 study in Glaucoma, Open-AngleGlaukos · NCT04615403 · 33 enrolled · United States, Philippines
- Sep 25, 2023Phase 3 study in Glaucoma, Open-AngleGlaukos · NCT06061718 · 60 enrolled · Armenia
- Aug 30, 2024Phase 2 study in Glaucoma, Open-AngleGlaukos · NCT06582732 · 210 enrolled · Armenia
- Feb 1, 2025Phase 4 study in Glaucoma, Open-AngleGlaukos · NCT06848946 · 132 planned · United States
TargetBeta
“Prostanoid FP receptor agonist”ChEMBL 37, by rule
Other programs on PTGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| AGN-193408 | AbbVie | phase 2 | 1 |
Studies
The newest 60 of 63 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06848946Glaucoma, Open-Angle · United States | 4 | Recruiting | Glaukos | Aug 2026 | 132 |
| NCT06582732Glaucoma, Open-Angle · Armenia | 2 | Completed | Glaukos | Nov 2, 2023 | 210 |
| NCT06061718Glaucoma, Open-Angle · Armenia | 3 | Active, not recruiting | Glaukos | Mar 18, 2024 | 60 |
| NCT04615403Glaucoma, Open-Angle · United States, Philippines | 2 | Completed | Glaukos | Feb 28, 2022 | 33 |
| NCT03965052Glaucoma · Mexico | 1 | Completed | Laboratorios Sophia S.A de C.V. | Jul 2, 2019 | 24 |
| NCT02914509Glaucoma, Open-Angle · United States | 3 | Completed | Ocular Therapeutix | Mar 30, 2019 | 565 |
| NCT02873806Glaucoma, Open-Angle · Armenia | 4 | Completed | Glaukos | Nov 8, 2019 | 53 |
| NCT02312544Glaucoma · United States | 2 | Completed | Ocular Therapeutix | Sep 2015 | 72 |
| NCT02003391Glaucoma, Open-Angle | 4 | Completed | Alcon | May 2015 | 157 |
| NCT01995136Low Tension Glaucoma · Japan | 4 | Completed | Alcon | Jun 2014 | 32 |
| NCT01696383Glaucoma | 4 | Withdrawn | Alcon | Feb 2013 | 0 |
| NCT01664039Glaucoma | 4 | Completed | Alcon | Jun 2014 | 104 |
| NCT01658839Glaucoma | 1 | Completed | Alcon | Jul 2013 | 25 |
| NCT01652664Hydrophthalmos | 3 | Completed | Alcon | Mar 2014 | 184 |
| NCT01510145Glaucoma, Open-Angle | 4 | Completed | Alcon | May 2013 | 191 |
| NCT01510132Glaucoma, Open-Angle | 4 | Withdrawn | Alcon | Jan 2012 | 0 |
| NCT01493427Glaucoma, Open-Angle | 4 | Completed | Alcon | Feb 2013 | 202 |
| NCT01464424Glaucoma | 4 | Completed | Alcon | Jun 2012 | 84 |
| NCT01453855Glaucoma, Open-Angle | 3 | Completed | Alcon | Aug 2012 | 1,099 |
| NCT01452009Glaucoma, Open-Angle | 3 | Withdrawn | Alcon | Dec 2011 | 0 |
| NCT01444040Glaucoma, Open-Angle · Armenia | 4 | Completed | Glaukos | Mar 28, 2019 | 196 |
| NCT01443988Glaucoma, Open-Angle · Armenia | 4 | Completed | Glaukos | Jan 2017 | 101 |
| NCT01336569Glaucoma · United States | 4 | Completed | Alcon | Mar 2012 | 50 |
| NCT01327599Glaucoma, Open-Angle | 4 | Completed | Alcon | Nov 2012 | 60 |
| NCT01298687Glaucoma, Open-Angle | 2 | Completed | Alcon | Apr 2011 | 67 |
| NCT01230736Glaucoma · Germany | 4 | Completed | Alcon | Feb 2011 | 105 |
| NCT01114893Glaucoma, Open-Angle · United States | 2 | Completed | Alcon | May 2010 | 60 |
| NCT00966940Glaucoma | 4 | Completed | Alcon | Mar 2010 | 51 |
| NCT00928590Glaucoma, Open-Angle | 3 | Completed | Alcon | Nov 2010 | 155 |
| NCT00872651Glaucoma, Open-Angle · China | 3 | Completed | Alcon | Nov 2011 | 242 |
| NCT00848536Glaucoma, Open-Angle | 3 | Completed | Alcon | Jan 2010 | 371 |
| NCT00847483Glaucoma · United States | 4 | Completed | Viatris | Aug 2002 | 375 |
| NCT00798759Glaucoma, Open-Angle | 4 | Completed | Alcon | May 2009 | 236 |
| NCT00767494Glaucoma · Belgium | 3 | Terminated | Alcon | Feb 2009 | 17 |
| NCT00767481Glaucoma · Mexico | 3 | Terminated | Alcon | Feb 2009 | 6 |
| NCT00763061Glaucoma · United States | 4 | Completed | Alcon | Apr 2008 | 111 |
| NCT00761319Glaucoma, Open-Angle | 3 | Completed | Alcon | Sep 2009 | 705 |
| NCT00762645Glaucoma, Angle-Closure | 4 | Completed | Alcon | May 2008 | 30 |
| NCT00760539Glaucoma, Open-Angle · Japan | 3 | Completed | Alcon | Dec 2008 | 87 |
| NCT00759239Glaucoma, Open-Angle · United Kingdom | 4 | Completed | Alcon | Jan 2011 | 36 |
| NCT00758342Intraocular Pressure | 4 | Terminated | Alcon | Mar 2008 | 37 |
| NCT00708422Glaucoma | 4 | Completed | Alcon | Aug 2009 | 231 |
| NCT00690794Glaucoma, Open-Angle | 3 | Completed | Alcon | May 2009 | 726 |
| NCT00672997Glaucoma, Open-Angle | 3 | Completed | Alcon | Dec 2008 | 301 |
| NCT00670033Ocular Hypertension | 2 | Completed | Alcon | Sep 2008 | 158 |
| NCT00527592Glaucoma, Open-Angle | 4 | Completed | Alcon | Aug 2008 | 54 |
| NCT00527501Glaucoma, Open-Angle · United States | 2 | Completed | Alcon | Dec 2007 | 136 |
| NCT00519753Glaucoma · Germany | 4 | Completed | Alcon | Dec 2008 | 522 |
| NCT00508469Glaucoma, Open-Angle · Spain | 4 | Completed | Alcon | Jan 2010 | 102 |
| NCT00471380Glaucoma · Italy | 4 | Completed | Alcon | Oct 2008 | 46 |
| NCT00471068Glaucoma, Open-Angle · Portugal | 4 | Terminated | Alcon | Aug 2008 | 46 |
| NCT00468988Glaucoma · United States | 4 | Completed | Alcon | Jul 2007 | 30 |
| NCT00465803Glaucoma, Open-Angle · United States | 3 | Completed | Alcon | Jan 2009 | 81 |
| NCT00444665Glaucoma · United States | 4 | Completed | Alcon | Aug 2007 | 750 |
| NCT00333125Glaucoma | 3 | Completed | Alcon | Feb 2007 | 319 |
| NCT00311389Glaucoma, Open-Angle · Belgium | 3 | Completed | Alcon | Sep 2004 | 408 |
| NCT00293800Glaucoma, Open-Angle | 3 | Completed | Alcon | Dec 2005 | 173 |
| NCT00293787Glaucoma, Open-Angle | 3 | Completed | Alcon | Aug 2005 | 156 |
| NCT00288951Glaucoma, Open-Angle | 3 | Completed | Alcon | Jun 2005 | 690 |
| NCT00061503Glaucoma · United States | 4 | Completed | Alcon | Mar 2004 |
How it is read
Names in the registry
- “Travoprost”, 6 entries
- “Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)”, 5 entries
- “Travoprost 0.004% / Timolol maleate 0.5%”, 2 entries
- “Travoprost 0.004% ophthalmic solution”, 2 entries
- “Travoprost ophthalmic solution, 0.004%”, 2 entries
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 42 studies
- Glaucoma, 20 studies
- Glaucoma, Angle-Closure, 2 studies
- Low Tension Glaucoma, 1 study
- Hydrophthalmos, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.